Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Elevated aldosterone

OHF is almost exclusively excreted without undergoing -ring reduction and conjugation and can be measured in urine by HPLC-MS. A useful diagnostic ratio is that of 18-OHF UFF, which is normally about 5 1 and rises to 50 1 in GRA. Serum analysis is used to measure aldosterone (elevated in the disorder) and cortisol, but not typically for 18-OHF. [Pg.590]

Two clinical forms are seen, one (so-called I), which has low plasma aldosterone, elevated corticosterone, and normal 18-hydroxy B the second ( II) has highly elevated 18-hydroxy and normal B. Only MS/MS methods for aldosterone and corticosterone are currently available. [Pg.592]

Dexamethasone-suppressible hyperaldosteronism Aldosteronism (elevated aldosterone production)... [Pg.2910]

Hyperaldosteronism is accompanied by elevation of blood pressure (115), and can be treated with an aldosterone antagonist, eg, spironolactone (117) which... [Pg.107]

It is well accepted that hypertension is a multifactorial disease. Only about 10% of the hypertensive patients have secondary hypertension for which causes, ie, partial coarctation of the renal artery, pheochromacytoma, aldosteronism, hormonal imbalances, etc, are known. The hallmark of hypertension is an abnormally elevated total peripheral resistance. In most patients hypertension produces no serious symptoms particularly in the early phase of the disease. This is why hypertension is called a silent killer. However, prolonged suffering of high arterial blood pressure leads to end organ damage, causing stroke, myocardial infarction, and heart failure, etc. Adequate treatment of hypertension has been proven to decrease the incidence of cardiovascular morbidity and mortaUty and therefore prolong life (176—183). [Pg.132]

Diuretics are often required in addition to the sodium restriction described previously. Spironolactone and jurosemide form the basis of pharmacologic therapy for ascites. Spironolactone is an aldosterone antagonist and counteracts the effects of activation of the renin-angiotensin-aldosterone system. In hepatic disease not only is aldosterone production increased, but its half-life is prolonged because it is hepatically metabolized. Spironolactone acts to conserve the potassium that would be otherwise excreted because of elevated aldosterone levels. [Pg.332]

The use of a -blockers within 24 hours is strongly advised, if possible. Nitroglycerin will be indicated within 48 hours to control persistent ischemia and elevated blood pressure. ACE-inhibitor therapy for long term use has to be started in the convalescence phase. Long-term aldosterone blockade is also advised. [Pg.590]

Angiotensin II stimulates aldosterone synthesis and secretion from the glomerulosa cells of the adrenal cortex. The aldosterone secretion induced by angiotensin II in humans is not accompanied by an increase in glucocorticoid plasma levels. Chronic administration of angiotensin II will maintain elevated aldosterone secretion for several days to weeks unless hypokalemia ensues. [Pg.210]

In situations of known renin-angiotensin-aldosterone involvement, such as in hypertension secondary to renal disease (i.e., renovascular hypertension), diuretics probably should not be used because they further elevate plasma renin. [Pg.226]

Adrenocorticoid hormones are produced in the adrenal glands. They regulate a variety of metaholic processes. The most important mineralo-corticoid is aldosterone, an aldehyde as well as a ketone, which regulates the reahsorption of sodium and chloride ions in the kidney, and increases the loss of potassium ions. Aldosterone is secreted when hlood sodium ion levels are too low to cause the kidney to retain sodium ions. If sodium levels are elevated, aldosterone is not secreted, so some sodium will he lost in the urine and water. Aldosterone also controls swelling in the tissues. [Pg.359]

Autonomic and hormonal control of cardiovascular function. Note that two feedback loops are present the autonomic nervous system loop and the hormonal loop. The sympathetic nervous system directly influences four major variables peripheral vascular resistance, heart rate, force, and venous tone. It also directly modulates renin production (not shown). The parasympathetic nervous system directly influences heart rate. In addition to its role in stimulating aldosterone secretion, angiotensin II directly increases peripheral vascular resistance and facilitates sympathetic effects (not shown). The net feedback effect of each loop is to compensate for changes in arterial blood pressure. Thus, decreased blood pressure due to blood loss would evoke increased sympathetic outflow and renin release. Conversely, elevated pressure due to the administration of a vasoconstrictor drug would cause reduced sympathetic outflow, reduced renin release, and increased parasympathetic (vagal) outflow. [Pg.122]

Liver disease is often associated with edema and ascites in conjunction with elevated portal hydrostatic pressures and reduced plasma oncotic pressures. Mechanisms for retention of Na+ by the kidney in this setting include diminished renal perfusion (from systemic vascular alterations), diminished plasma volume (due to ascites formation), and diminished oncotic pressure (hypoalbuminemia). In addition, there may be primary Na+ retention due to elevated plasma aldosterone levels. [Pg.340]

Aliskiren is the most advanced of these and the first to be approved for the treatment of hypertension. In healthy subjects, aliskiren produces a dose-dependent reduction in plasma renin activity and Ang I and II and aldosterone concentrations. In patients with hypertension, many of whom have elevated plasma renin levels, aliskiren suppresses plasma renin activity and causes dose-related reductions in blood pressure similar to those produced by ACE inhibitors (Figure 17-3). The safety and tolerability of aliskiren appear to be comparable to angiotensin antagonists and placebo. [Pg.378]

Primary aldosteronism usually results from the excessive production of aldosterone by an adrenal adenoma. However, it may also result from abnormal secretion by hyperplastic glands or from a malignant tumor. The clinical findings of hypertension, weakness, and tetany are related to the continued renal loss of potassium, which leads to hypokalemia, alkalosis, and elevation of serum sodium concentrations. This syndrome can also be produced in disorders of adrenal steroid biosynthesis by excessive secretion of deoxycorticosterone, corticosterone, or 18-hydroxycorticosterone—all compounds with inherent mineralocorticoid activity. [Pg.883]

In profile analysis, I shows low THAldo and 18-hydroxyTHA (the major 18-hydroxy corticosterone metabolite), but high excretions of THAs and THBs [26, 33]. In II, THAldo is low, the THAs and THBs normal, but 18-OH-THA is often grossly elevated. Representative excretions of several patients with both forms of the disorder are shown in Table 5.3.11. However, it must be emphasized that even if the steroid phenotype appears to have two forms, a single enzyme is responsible for aldosterone synthesis. [Pg.593]

Galactorrhea, amenorrhea, gynecomastia, impotence seconder y to hyperprolactinemia, fluid retention seconder y to transient elevation of aldosterone... [Pg.138]


See other pages where Elevated aldosterone is mentioned: [Pg.97]    [Pg.2031]    [Pg.22]    [Pg.97]    [Pg.2031]    [Pg.22]    [Pg.139]    [Pg.142]    [Pg.275]    [Pg.432]    [Pg.480]    [Pg.481]    [Pg.811]    [Pg.357]    [Pg.217]    [Pg.13]    [Pg.25]    [Pg.37]    [Pg.98]    [Pg.217]    [Pg.202]    [Pg.220]    [Pg.130]    [Pg.160]    [Pg.158]    [Pg.243]    [Pg.180]    [Pg.208]    [Pg.371]    [Pg.372]    [Pg.141]    [Pg.222]    [Pg.373]    [Pg.17]    [Pg.61]    [Pg.98]   


SEARCH



Aldosterone

Aldosteronism

© 2026 chempedia.info